Er OON denied as duplicate or overlapping therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for er oon are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Extended-Release Opioids as Duplicate Therapy

UnitedHealthcare may deny an extended-release opioid (ER opioid) claim as "duplicate therapy" when its records show another long-acting or extended-release opioid already active on your account, or when a short-acting opioid is being dispensed concurrently in a way the plan's system flags as overlapping coverage. Automated pharmacy edits can trigger this denial even when the clinical picture clearly justifies both agents — for example, a transition between formulations or a legitimate short-acting rescue alongside a scheduled extended-release product.

## Why This Denial Is Appealable

A duplicate-therapy flag is an administrative determination, not a clinical one. If your prescriber has documented a distinct clinical rationale for each agent — different dosing intervals, formulation switch, or a scheduled-plus-rescue regimen — that documentation directly refutes the premise of the denial. Insurers must base coverage decisions on the actual clinical record, not solely on pharmacy-system flags.

## Federal Appeal Framework

• Internal appeal (Level 1): Submit within the timeframe shown on your denial letter (typically 180 days for non-grandfathered ACA plans; ERISA plans vary). The plan must respond within 60 days for pre-service or 60 days post-service.
• Expedited review: If continuing therapy is urgent, request expedited internal appeal — the plan must respond within 72 hours.
• External review (ACA §2719 / ERISA §503): After exhausting internal appeals, you have the right to independent external review. The external-review request window is typically four months from the final internal denial. An Independent Review Organization (IRO) makes a binding decision.

## Appeal Process and Timeline

1. Obtain the Explanation of Benefits (EOB) and the written denial letter identifying the specific duplicate-therapy criterion triggered. 2. Ask your prescriber to write a detailed letter of medical necessity addressing the distinct clinical role of each opioid agent. 3. Request UHC's clinical coverage policy for the specific opioid formulation to identify every criterion you must address. 4. Submit the internal appeal with all documentation, ideally within 30 days to preserve maximum time for escalation. 5. If denied again, file for external review immediately.

## Documentation to Gather

• Diagnosis confirmation: Chart notes establishing the underlying pain condition, its severity, and functional impact.
• Prior-treatment history: Dates, agents tried, doses inadequate or not tolerated — with prescriber notes explaining why each was insufficient.
• Clinical rationale for concurrent or transitional therapy: A prescriber letter explaining why both agents are simultaneously necessary or why a switch is in progress, distinguishing this from true duplication.
• Pharmacy records: Showing actual dispensing dates to clarify there is no true overlap, or that overlap is medically managed.

## Criteria-Mapping Structure

Obtain UHC's published coverage policy for this drug. List each criterion the policy sets. For each criterion, document the specific chart entry that satisfies it — date, provider name, clinical finding. Your appeal letter should mirror this structure point by point, so the reviewer can confirm compliance without ambiguity.